These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 1423948)

  • 1. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers.
    Kroon C; ten Hove WR; de Boer A; Kroon JM; van der Pol JM; Harthoorn-Lasthuizen EJ; Schoemaker HC; van der Meer FJ; Cohen AF
    Circulation; 1992 Nov; 86(5):1370-5. PubMed ID: 1423948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variable and circadian response to a fixed high-dose (12 500 IU twice daily) subcutaneous heparin regimen after thrombolytic therapy for acute myocardial infarction.
    Violaris AG; Trudgill NJ; Rowlands L; Gunn J; Tsikaderis D; Campbell S
    Coron Artery Dis; 1994 Mar; 5(3):257-65. PubMed ID: 8199741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
    Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
    Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers.
    Holst J; Lindblad B; Bergqvist D; Garre K; Nielsen H; Hedner U; Ostergaard PB
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):795-803. PubMed ID: 7865687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans.
    Baughman RA; Kapoor SC; Agarwal RK; Kisicki J; Catella-Lawson F; FitzGerald GA
    Circulation; 1998 Oct; 98(16):1610-5. PubMed ID: 9778325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.
    Fossler MJ; Barrett JS; Hainer JW; Riddle JG; Ostergaard P; van der Elst E; Sprogel P
    Am J Health Syst Pharm; 2001 Sep; 58(17):1614-21. PubMed ID: 11556655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing an institution-specific therapeutic range for heparin.
    Volles DF; Ancell CJ; Michael KA; Mullins DM; Humphries JE
    Am J Health Syst Pharm; 1998 Oct; 55(19):2002-6. PubMed ID: 9784787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers.
    Depasse F; González de Suso MJ; Lagoutte I; Fontcuberta J; Borrell M; Samama MM
    Thromb Res; 2003 Jan; 109(2-3):109-17. PubMed ID: 12706639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of skinfold thickness on heparin absorption.
    Kroon C; de Boer A; Kroon JM; Schoemaker HC; van den Meer FJ; Cohen AF
    Lancet; 1991 Apr; 337(8747):945-6. PubMed ID: 1678033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.
    Granger CB; Hirsch J; Califf RM; Col J; White HD; Betriu A; Woodlief LH; Lee KL; Bovill EG; Simes RJ; Topol EJ
    Circulation; 1996 Mar; 93(5):870-8. PubMed ID: 8598077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related differences in heparin response.
    Ignjatovic V; Furmedge J; Newall F; Chan A; Berry L; Fong C; Cheng K; Monagle P
    Thromb Res; 2006; 118(6):741-5. PubMed ID: 16360197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
    Siguret V; Pautas E; Février M; Wipff C; Durand-Gasselin B; Laurent M; Andreux JP; d'Urso M; Gaussem P
    Thromb Haemost; 2000 Nov; 84(5):800-4. PubMed ID: 11127859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
    Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B
    Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.